Sanochemia Pharmazeutika Ag

Beate Kälz

Stefan Welzig

József Gungl

Klaus Gerdes

Werner Frantsits

Christina Abrahamsberg

Jan Rothenburger

Laszlo Czollner

Federico Gaeta

Gregor Medinger

Matthias Treu

Ulrich Jordis

Johannes Frohlich

Raffael Schuecker

Roswitha Braunrath

Manfred Hirnschall

Jòzsef Gungl

Photodynamic therapy of tumors such as bladder tumors includes photosensitizing with a photosensitizer that is a complex or a compound of hypericin and a polymeric complexing agent. The photosensitizer is formed from an alkali salt of hypericin and the polymeric complexing agent. The alkali salt of hypericin is a sodium salt or a potassium salt. The complexing agent is a polyethylene glycol or a poly-N-vinyl amide.

Method for the production of a formulation of a hypericin salt

Photodynamic therapy, formulation usable for this purpose, and method for the production and use thereof

In the early detection of cancer, in particular bladder cancer, a photodynamic diagnosis uses, as a photosensitizer, a formulation that contains sodium hypericinate that is bonded to polyvinylpyrrolidone or complexed with polyvinylpyrrolidone.

Photodynamic diagnosis, formulations usable as photosensitizers for this purpose, method for the production and use thereof

The present disclosure is directed to methods for providing tolperisone having extremely low levels of 4-MMPPO (2-methyl-1-(4-methylphenyl)-propenone), as well as related compositions. The invention further relates to methods of treating a subject with tolperisone under conditions that limit exposure of the subject to tolerable levels of 4-MMPPO, among other features.

Compositions of tolperisone

The invention relates to a method for producing highly pure 2,4'-dimethyl-3-piperidino-propiophenone (tolperisone) (formula I) and the pharmaceutically acceptable salts, hydrochlorides, and hydrates thereof. The method allows the content of the undesired byproduct 2-methyl-1-(4-methylphenyl) propenone (4-MMPPO) to be kept significantly lower than in previously known methods. The invention further relates to active substance formulations which contain tolperisone and are suitable, among other things, for producing combination preparations used for treating patients suffering from Alzheimer's disease. The invention also relates to topical formulations, controlled release (CR) formulations, and transdermal therapeutic systems, such as active substance patches, which contain less than 50 ppm, preferably less than 10 ppm, more preferably less than 7 ppm, and most preferably less than 3 ppm or 0 ppm (i.e. less than the detectable amount) of the undesired byproduct 2-methyl-1-(4-methylphenyl) propenone (4-MMPPO) in relation to 100 percent by weight of active substance.

Process for the production of high-purity 2,4'-dimethyl-3-piperidino-propiophenone (tolperisone), pharmaceutical compositions that contain the latter, as well as active ingredient formulations that contain tolperisone

The invention relates to a method for producing an addition salt of 2,4'-dimethyl-3-piperidino-propiophenone (tolperisone) with a pharmaceutically acceptable acid, of formula (I). According to the invention, 4-methylpropiophenone is reacted with piperidine hydrochloride and 1,2-dioxolane in the presence of an acid serving as a catalyst, and the tolperisone obtained in the form of an acid addition salt is separated by filtering after the reaction mixture has cooled down 

Method for producing salts of tolperisone

Derivatives and analogs of galanthamine

Growing community of inventors

Steinbrunn, Austria

Beate Kälz